Aerosol Generation

Aerosol Drug Delivery

Aerosol Delivery of Biotherapeutics

Inhalation Toxicology



Press release February 20, 2019
Of the 15 million premature babies born annually around the world, one million die within the first month of life, and many of the 14 million of these infants who survive have childhood respiratory problems followed by a lifetime of serious health complications. Respiratory distress syndrome, RDS, is the single most important cause of mortality and morbidity in preterm infants. The instillation of liquid surfactant into the lungs of babies following intubation or penetration of a catheter to instill surfactant is a traumatic and results in preventable complications.  KAER Biotherapeutics has been awarded a Phase I SBIR grant of $0.3M from the National Heart Lung and Blood Institute of the National Institutes of Health “Non-Invasive Surfactant Aerosol Therapy for RDS” to demonstrate that delivery of lung surfactant aerosols to an animal model of RDS using KAER’s SUPRAER® technology can improve respiratory function.  These studies will be conducted in conjunction with Professor Gregory Heldt, M.D. Success in these endeavors will provide the proof of concept for the non-invasive delivery of surfactant aerosols to prematurely born babies who have not yet produced enough surfactant to enable normal respiratory function.

This SBIR award further expands KAER’s capabilities for providing lifesaving aerosol therapies for critically ill patients with debilitating respiratory function.  This includes KAER’s production of a clinical device, SUPRAER-Clinic, to treat adult patients who have acute lung injury so as to prevent their rapid deterioration into acute respiratory distress syndrome, ARDS.  ARDS has a mortality rate of 40%.  There are no approved drugs to treat ARDS.  This program is supported by a Phase II SBIR award of $2M from the National Heart Lung and Blood Institute. Professor Matthay, M.D, at the University of San Francisco is a co-investigator of the project.  Dr. Yeates, CEO of KAER and the Principal investigator of both of these NIH awards affirms that KAER is committed to saving lives in both neonates and adults in respiratory distress while reducing heath care costs in the short and long term.

Further applications of KAER’s SUPRAER’s technology include the treatment of idiopathic pulmonary fibrosis, hospital acquired pneumonia, NSCLC and other respiratory diseases.

Related Publications

Heng, X., and Yeates, D.B. (2018). Generation of high concentrations of respirable solid-phase aerosols from viscous fluids. Aerosol Science and Technology, 52(8):933-952.

Heng, X., Yi, J., and Yeates, D.B. (2019) Fluidic and thermal properties of heliox enable the efficient generation and delivery of high concentrations of solid-phase, fine particles aerosols from viscous liquids Aerosol Science and Technology,

Yeates, D.B., Surfactant Aerosol Therapy for nRDS and ARDS. (2019) In: ‘Inhalation Aerosols, Physical and Biological Basis for Therapy’, InformaHealthCare/CRC Press/Taylor & Francis, Third Edition. Eds. A.J. Hickey and H.M. Mansour. Chapter 21 327-342.

Yeates, D. B. and Mortensen J.  Deposition and Clearance, In: Murray JF, Nadel JA: Textbook of Respiratory Medicine, ed 3. Philadelphia, WB Saunders Company, Vol. 1. Chapter 15 pp 349-384, 2000.

News Release:June 20 2018

Dr Yeates co-chaired the session on Formulation and Smart DDS (Drug Delivery Science) and presenting "Delivery of Aerosolized Biologics at High Dose Rates" at " BIT's 16th Annual Congress of International Drug discovery Science and Technology", August 16-18, Boston, 2018

September 10-112018 KAER is Partner in DDF Summit, Drug delivery and Formulation, San Francisco



June 2018 KAER exhibited at Respiratory Drug Delivery, Tucson, AZ.


June 1, 2017

Dr. Yeates presented "Augmentation of the Generation, Processing and Delivery of Surfactant and Macromolecule Aerosols with Heliox", 21 ISAM-Congress, Santa Fe, NM, June 3-7, 2017.





May 3, 2017

KAER, a Start-Up Breakthrough Finalist, presented at Start-Up Stadium, BIO, San Diego, June 21, 2017 (

BIO Finalist



October 2016

Dr. Yeates presented "Aerosol Surfactant Replacement Therapy for Patients with Acute Respiratory Distress Syndrome" at the Life Sciences Summit, New York, NY, November 2-3, 2016.LifeSciense



Dr. Yeates presented: "Generation of Respirable Particles from Surfactant Suspensions and Viscous Solutions at High Dose Rates", Drug Delivery to the Lungs, Edinburgh, UK, December 7-9, 2016.


April 30, 2016

A potential new treatment for Acute Respiratory Distress Syndrome and Acute Lung Injury (ARDS/ALI) has been developed using an aerosolized surfactant. KAER has incorporated a new patent-pending nozzle technology into its SUPRAER� aerosol delivery platform. For the first time, surfactant aerosols less than 4 microns in diameter, can be delivered at 2 mg/second. In conjunction with negative pressure ventilation or incorporation of this technology into a ventilator would facilitate the delivery of a therapeutically-needed 1 g of surfactant aerosol to the patient�s deep lung in 20 minutes. This surfactant is targeted at replacing the inflammation-induced inactivated surfactant in these critically ill patients and reversing the resultant hypoxemia by reducing the surface tension in the deep lung, opening alveoli, resolving excess lung fluid (edema), decreasing the work of breathing, and thus improving gas exchange. KAER is working toward reducing the present mortality of these syndromes to considerably less than the current 43%.

The SUPRAER technology can be used to aerosolize viscous solutions and suspensions of any drug. Using 20% solutions of polyvinylpyrrolidone, as a protein or drug surrogate, aerosols of less than 4 microns in diameter have been generated at output rates up to 4 mg/second. A typical 7-second inhalation would deliver up to 28 mg during each breath or a therapeutically-needed dose of up to 280 mg in just 10 breaths. This is game-changing for the rapid delivery of anti-infectives and anticancer agents to the lungs.

The final size of these drug aerosol particles can be tailored for optimum deposition in the lungs of small and large animals as well as humans. These new developments add to KAER�s worldwide intellectual property portfolio on aerosol generation and processing for respiratory drug delivery. A comprehensive set of data generated with KAER�s new nozzles incorporated into the SUPRAER platform was presented at the Respiratory Drug Delivery conference in Phoenix, AZ, April 18-19, 2016. e April 30, 2016



March 14, 2016

KAER exhibited at the Society of Toxicology in New Orleans, March 14-16, 2016.


November 15, 2015

KAER is a finalist for a 2016 Patrick Soon Shiong Innovation Award for its SUPRAER aerosol delivery technology.

September 1, 2015

National Heart Lung and Blood Institute of the National Institutes of Health award KAER Biotherapeutics a Phase I SBIR grant “Aerosol delivery of Surfactant for ARDS” commencing September 1, 2015. 

Acute respiratory distress syndrome, ARDS, including acute lung injury ALI are of multifactorial etiology and afflicts 190,000 Americans each year and 18% of all ventilated patients. Despite sophisticated intensive care, the mortality rate ranges between 15 and 72% with a mean of 43%.  Patients with ARDS have impaired surfactant function and continued inflammation-induced metabolism of surfactant indicating that a single treatment with surfactant is inadequate. Our target is to demonstrate that using KAER’s SUPRAER technologies, clinically relevant doses of surfactant aerosols can be generated and delivered within a short treatment period.  The delivery of surfactant in a gentler, non-invasive manner would empower the clinician to provide improved life support and potentially a marked improvement in survival.

Dr. Yeates, Principal Investigator of this project noted, “This important new technological innovation will also be applicable to treat other diseases of the lungs that require drugs whose efficacy depends on high doses being delivered in a short time.  Short treatment times lead to better patient adherence, efficacy and improved heath care.”


October 13, 2015

KAER exhibited at the Association of Inhalation Toxicologist, Cambridge, UK, Oct 13-15, 2015.

March 20, 2015

KAER exhibited at the Society of Toxicology, San Diego, March 20-23 2015.


Nov 18-20,2014

Dr. Yeates presented "Aerosol delivery of Biotherapeutics:New Technologies" at Drug Delivery Systems 2014, Suzhou, China.


September 22-24, 2014

KAER exhibited at the AIT-ISAM joint conference "Inhaled Medications from the Bench to the Bedside: Preclinical, Clinical and Technical Considerations for 'First in Human' and Beyond" Princeton, NJ, 2014.


May 4-8, 2014

KAER exhibited at the Respiratory Drug Delivery, Puerto Rico.


March 23-25, 2014

KAER exhibited at the Society of Toxicology Annual Meetin in Phoenix

September 11-12, 2013

Dr. Yeates presented, "A New Class of Aerosol Generation System for High Dose-Rate Aerosol Delivery of Biotherapeutics" at: Inhalation Drug Delivery, Berlin, Germany.

Logo for CHpi





June 11, 2013

KAER presented at NHLBI San Diego Innovation Conference, San Diego, CANIHLBI logo


May 21, 2013

Dr. Yeates presented a poster "High Dose Rate generation of fine particle aerosols of antibodies with SUPRAER compared to two mesh-type nebulizers." at Respiratory Drug Delivery in Berlin. RDD E



April 20-23, 2013

KAER exibited at the ISAM conference in Chapel Hill, N. Carolina and Donovan Yeates presented the poster "Generation of Respirable Antibody Aerosols". ISAM 2013 logo




March 12, 2013

Frost & Sullivan present to Donovan Yeates, CEO of KAER, the 2012 North American Technology Innovation Award for Aerosol Drug Delivery

Dr. Yeates receives Award

In recognition of SUPRAER�s technology and its importance in the drug delivery industry, Frost and Sullivan awarded KAER Biotherapeutics their 2012 North American Technology Innovation Award for Aerosol Drug Delivery. This award was based on metrics from 1 to 10 quantifying the following criteria: uniqueness of technology, new products/applications, impact on functionality, impact on customer value, and relevance of innovation to industry. The two top competitors average score was 5 and 4, whereas SUPRAER�s average score was 10. Request copy of full report


March 11-13, 2012

KAER Biotherapeutics exibited SUPRAER at the 2013 Society of Toxicology Conference in San Antonio.

Oct 16-17, 2012

KAER Biotherapeutics was presented by Dr. Yeates at IN3 medical Device Summit in San Francisco .

May 13-17, 2012

Dr. Yeates presented "SUPRAER: A PLATFORM FOR HIGH DOSE RATE DELIVERY OF BIOTHERAPEUTICS" at Respiratory Drug Delivery, Phoenix, AZ.

March, 11-15, 2012

Dr. Yeates Presented "COMPACT HIGH OUTPUT RESPIRABLE AEROSOL GENERATOR FOR BIOLOGICS" at Society of Toxicology, San Francisco, CA .

January 9-13, 2012

Dr. Yeates presented "New System for the Generation and Delivery of High Concentrations of Respirable Aerosols of Biologics and Large Labile Molecules at PepTalk in the Spray Drying and Emerging Technologies session, San Diego, CA.

Nov 3-5 2011

Dr. Yeates presented "SUPRAER: A New Aerosol Delivery Platform for High Dose-Rate Delivery of Biotherapeutics" in the Pulmonary Drug Delivery session of Drug Delivery Systems in Shenzhen, China.

June 18-21, 2011

SUPRAER was launched at the International Society for Aerosols in Medicine in Rotterdam, NL.




Copyright KAER Biotherapeutics Corporation. All Rights Reserved